Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne Corporation (NASDAQ: TECH) reported strong financial results for Q3 FY2022, with organic revenue growth of 17% to $290.4 million. GAAP EPS was $1.48, up from $1.12 last year, while adjusted EPS rose to $2.14 from $1.80. Key highlights include 16% organic growth in Protein Sciences and 19% in Diagnostics and Genomics. The company also announced a partnership with Thermo Fisher Scientific for the ExoTRU kidney transplant rejection test. Adjusted operating income increased 17% to $114.6 million, maintaining a robust adjusted operating margin of 39.6%.

Bio-Techne Corporation (NASDAQ: TECH) will have its President and CEO, Chuck Kummeth, present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 2:40 p.m. PST. Interested parties can access a live webcast via the company’s Investor Relations website.

Bio-Techne is a key player in creating purified proteins and reagent solutions, with products that cater to biomedical researchers and clinical laboratories. In fiscal 2021, Bio-Techne reported approximately $931 million in net sales. The company has around 2,700 employees globally.

Bio-Techne Corporation (NASDAQ: TECH) plans to host a conference call on May 4, 2022, at 8:00 a.m. CDT to discuss its third quarter fiscal 2022 financial results. Interested parties can join via dial-in or webcast, with the details provided in the release. A replay will be available from 11:00 a.m. CDT on May 4 until 11:00 p.m. CDT on June 4. Bio-Techne reported approximately $931 million in net sales for fiscal 2021 and employs around 2,700 staff globally, focusing on high-quality biological products and diagnostic tools.

Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), have launched the Simple Plex™ HEK 293 HCP 3G assay for automated impurity testing on the Ella™ platform. This innovative assay enhances viral production workflows by accurately quantifying host cell protein (HCP) impurities in a rapid, 90-minute process. It promises improved consistency and reduced variability compared to traditional methods, leveraging Cygnus's established HCP detection technology. The collaboration aims to support the growing cell and gene therapy market.

Bio-Techne Corporation (NASDAQ: TECH) will present at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 11:15 a.m. EDT. Will Geist, President of the Protein Sciences Segment, will lead the presentation, which will be accessible via the company's Investor Relations website. Bio-Techne specializes in developing high-quality proteins and reagents, supporting biomedical research and clinical diagnostics. In fiscal 2021, the company reported approximately $931 million in net sales and employs around 2,700 staff globally.

Bio-Techne Corporation (NASDAQ: TECH) will have CEO Chuck Kummeth present at the Barclays Global Healthcare Conference on March 16, 2022, at 8:30 a.m. EST. A live webcast will be available on Bio-Techne's Investor Relations website. The company specializes in high-quality purified proteins and reagent solutions, generating approximately $931 million in net sales in fiscal 2021. Its diverse product range supports scientific investigations and clinical diagnostics, impacting drug discovery and disease diagnosis.

Bio-Techne Corporation (NASDAQ: TECH) has announced that Executive Vice President and CFO Jim Hippel will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. EST. The presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website. The company, a key player in the development of purified proteins and reagent solutions, recorded approximately $931 million in net sales in fiscal 2021 and employs around 2,700 staff worldwide, focusing on diagnostics and genomic tools.

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, the Executive Vice President and CFO, will present at the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 10:15 a.m. EST. The presentation will be accessible via the company's Investor Relations website. Bio-Techne is a leading developer of purified proteins and reagent solutions, including diagnostics and genomic tools, generating approximately $931 million in net sales in fiscal 2021 with around 2,700 employees globally.

Bio-Techne Corporation (NASDAQ: TECH) has partnered with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test. This non-invasive liquid biopsy assay provides critical allograft health information, aiding in the management of kidney transplant patients by distinguishing between T-cell mediated rejection and antibody mediated rejection. Developed with the Azzi Laboratory at Harvard Medical School's Transplantation Research Center, the ExoTRU assay meets a significant need in patient care and has potential for market leadership in liquid biopsies.